Bristol-Myers Squibb(US:BMY) 智通财经网·2025-12-03 15:34Core Viewpoint - Bristol-Myers Squibb (BMY.US) shares rose by 5% to $50.67 following the announcement of increased participant recruitment for a late-stage trial assessing the safety and efficacy of Cobenfy for Alzheimer's disease-related psychosis [1] Group 1: Company Developments - Bristol-Myers Squibb announced plans to recruit more participants for a late-stage trial of Cobenfy, aimed at evaluating its safety and efficacy in treating Alzheimer's disease-related psychosis [1] - The decision to increase recruitment was made after identifying "non-compliance" issues at a few trial sites related to clinical study execution, leading to the exclusion of patient data from the primary analysis [1] Group 2: Product Information - Cobenfy is currently approved for the treatment of adult schizophrenia and has the potential to become the first drug therapy based on muscarinic receptor agonism targeting agitation and psychosis [1] - Results from the ADEPT program, which includes ADEPT-2, ADEPT-1, and ADEPT-4 trials for Alzheimer's disease-related psychosis, are expected to be revealed by the end of 2026 [1]